🇺🇸 timolol ophthalmic solution in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthenia — 2 reports (15.38%)
  2. Fatigue — 2 reports (15.38%)
  3. Off Label Use — 2 reports (15.38%)
  4. Alopecia — 1 report (7.69%)
  5. Atrioventricular Septal Defect — 1 report (7.69%)
  6. Bradycardia — 1 report (7.69%)
  7. Cardiac Arrest — 1 report (7.69%)
  8. Chest Pain — 1 report (7.69%)
  9. Confusional State — 1 report (7.69%)
  10. Congenital Mitral Valve Incompetence — 1 report (7.69%)

Source database →

timolol ophthalmic solution in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is timolol ophthalmic solution approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for timolol ophthalmic solution in United States?

Allergan is the originator. The local marketing authorisation holder may differ — check the official source linked above.